• 9128 Citations
19972020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Developing new and better treatment approaches to lymphoma and chronic lymphocytic leukemia.

Areas of Clinical Interest

Fingerprint Dive into the research topics where Brad Kahl is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 17 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology

Wierda, W. G., Byrd, J. C., Abramson, J. S., Bilgrami, S. F., Bociek, G., Brander, D., Brown, J., Chanan-Khan, A. A., Chavez, J. C., Coutre, S. E., Davis, R. S., Fletcher, C. D., Hill, B., Kahl, B. S., Kamdar, M., Kaplan, L. D., Khan, N., Kipps, T. J., Lim, M. S., Ma, S. & 10 others, Malek, S., Mato, A., Mosse, C., Shadman, M., Siddiqi, T., Stephens, D., Sundaram, S., Wagner, N., Dwyer, M. & Sundar, H., Feb 1 2020, In : Journal of the National Comprehensive Cancer Network : JNCCN. 18, 2, p. 185-217 33 p.

Research output: Contribution to journalArticle

  • 5 Scopus citations

    Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma

    Guy, D. & Kahl, B. S., Oct 2020, In : Hematology/Oncology Clinics of North America. 34, 5, p. 861-870 10 p.

    Research output: Contribution to journalReview article

  • Initial Treatment of Early Stage and Low Tumor Burden Follicular Lymphoma

    Cohen, J. B. & Kahl, B. S., Jan 1 2020, (Accepted/In press) In : Hematology/Oncology Clinics of North America.

    Research output: Contribution to journalReview article

  • 1 Scopus citations

    Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

    Diefenbach, C. S., Hong, F., Ambinder, R. F., Cohen, J. B., Robertson, M. J., David, K. A., Advani, R. H., Fenske, T. S., Barta, S. K., Palmisiano, N. D., Svoboda, J., Morgan, D. S., Karmali, R., Sharon, E., Streicher, H., Kahl, B. S. & Ansell, S. M., Sep 2020, In : The Lancet Haematology. 7, 9, p. e660-e670

    Research output: Contribution to journalArticle

  • 1 Scopus citations

    MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial

    Pott, C., Sehn, L. H., Belada, D., Gribben, J., Hoster, E., Kahl, B., Kehden, B., Nicolas-Virelizier, E., Spielewoy, N., Fingerle-Rowson, G., Harbron, C., Mundt, K., Wassner-Fritsch, E. & Cheson, B. D., Feb 1 2020, In : Leukemia. 34, 2, p. 522-532 11 p.

    Research output: Contribution to journalArticle

    Open Access
  • 2 Scopus citations